
GSK plc (GSK:LSE) Strategic SWOT, PESTLE Analysis and Financial Insights - A 360° Review of Opportunities, Challenges and Risk, Corporate and ESG Strategies, Competitive Intelligence, Financial and Operational KPI’s, and Recent Trends
Description
Report Summary
GSK plc (GSK:LSE) Strategic SWOT, PESTLE Analysis and Financial Insights - A 360° Review of Opportunities, Challenges and Risk, Corporate and ESG Strategies, Competitive Intelligence, Financial and Operational KPI’s, and Recent Trends Report is a comprehensive and easily accessible overview of GSK plc's business operations. It provides a detailed analysis of the company's financial and strategic standing, as well as its position in the industry compared to competitors. The report includes several key features to facilitate decision-making and provide insights into the company's performance.
The report begins with in-depth information about GSK plc, including key insights, business segments, key executives, locations, products and services, historical events, corporate strategy, and management discussions. This section provides a solid foundation for understanding the company's key attributes.
Next, the report assesses GSK plc's strategic standing through various analyses. The ESG spotlight evaluates the company's environmental, social, and governance performance, providing insights into its sustainability efforts and ethical practices. The SWOT analysis examines the company's internal strengths and weaknesses, as well as external opportunities and threats. The PESTLE analysis evaluates the external factors impacting the company's operations and market environment. Additionally, By integrating these strategic analyses, the report offers a comprehensive understanding of GSK plc's overall strategic standing and supports informed decision-making and strategic planning.
The report also covers GSK plc's financial analysis basis of latest income statement, balance sheet, and cash flow statement. Key financial ratios related to profitability, asset turnover, credit, market, and long-term solvency are outlined, providing guidance for investment decisions. Furthermore, the report compares GSK plc's financial parameters with those of its competitors, offering a unique analysis of the competitive landscape. This information helps manage the business environment and improve sales activities by gaining insight into competitors' operations.
Finally, the report includes recent news and deal activities undertaken by GSK plc, enhancing awareness of the company's business trends, growth perspectives, and more.
Key Highlights
GSK plc is a British multinational pharmaceutical and biotechnology company with global headquarters in London. It was established in 2000 by a merger of Glaxo Wellcome and SmithKline Beecham, which was itself a merger of a number of pharmaceutical companies around the Smith, Kline and French firm. GSK aims to deliver impactful medicines, vaccines, and treatments, positively affecting the lives of 2.5 billion people by 2030. It invest heavily in research and development, utilizing advancements like AI and robotics for faster production. The company has a primary listing on the London Stock Exchange and is a constituent of the FTSE 100 Index. As of February 2024, it had a market capitalisation of £69 billion, the eighth largest on the London Stock Exchange. It offers drugs for the treatment of diseases such as HIV, respiratory, cancer, immuno-inflammation, anti-viral, central nervous system (CNS), metabolic, cardiovascular, and urogenital, anti-bacterial, dermatology and rare diseases. The company also offers over-the-counter (OTC) products for pain relief, oral health, nutrition, skin health and gastrointestinal diseases. GSK’s vaccine portfolio covers various diseases including hepatitis, diphtheria, tetanus, whooping cough, rotavirus and HPV infections, measles and bacterial meningitis, among others.
GSK plc in the News:-
GSK plc (GSK:LSE) Strategic SWOT, PESTLE Analysis and Financial Insights - A 360° Review of Opportunities, Challenges and Risk, Corporate and ESG Strategies, Competitive Intelligence, Financial and Operational KPI’s, and Recent Trends Report is a comprehensive and easily accessible overview of GSK plc's business operations. It provides a detailed analysis of the company's financial and strategic standing, as well as its position in the industry compared to competitors. The report includes several key features to facilitate decision-making and provide insights into the company's performance.
The report begins with in-depth information about GSK plc, including key insights, business segments, key executives, locations, products and services, historical events, corporate strategy, and management discussions. This section provides a solid foundation for understanding the company's key attributes.
Next, the report assesses GSK plc's strategic standing through various analyses. The ESG spotlight evaluates the company's environmental, social, and governance performance, providing insights into its sustainability efforts and ethical practices. The SWOT analysis examines the company's internal strengths and weaknesses, as well as external opportunities and threats. The PESTLE analysis evaluates the external factors impacting the company's operations and market environment. Additionally, By integrating these strategic analyses, the report offers a comprehensive understanding of GSK plc's overall strategic standing and supports informed decision-making and strategic planning.
The report also covers GSK plc's financial analysis basis of latest income statement, balance sheet, and cash flow statement. Key financial ratios related to profitability, asset turnover, credit, market, and long-term solvency are outlined, providing guidance for investment decisions. Furthermore, the report compares GSK plc's financial parameters with those of its competitors, offering a unique analysis of the competitive landscape. This information helps manage the business environment and improve sales activities by gaining insight into competitors' operations.
Finally, the report includes recent news and deal activities undertaken by GSK plc, enhancing awareness of the company's business trends, growth perspectives, and more.
Key Highlights
GSK plc is a British multinational pharmaceutical and biotechnology company with global headquarters in London. It was established in 2000 by a merger of Glaxo Wellcome and SmithKline Beecham, which was itself a merger of a number of pharmaceutical companies around the Smith, Kline and French firm. GSK aims to deliver impactful medicines, vaccines, and treatments, positively affecting the lives of 2.5 billion people by 2030. It invest heavily in research and development, utilizing advancements like AI and robotics for faster production. The company has a primary listing on the London Stock Exchange and is a constituent of the FTSE 100 Index. As of February 2024, it had a market capitalisation of £69 billion, the eighth largest on the London Stock Exchange. It offers drugs for the treatment of diseases such as HIV, respiratory, cancer, immuno-inflammation, anti-viral, central nervous system (CNS), metabolic, cardiovascular, and urogenital, anti-bacterial, dermatology and rare diseases. The company also offers over-the-counter (OTC) products for pain relief, oral health, nutrition, skin health and gastrointestinal diseases. GSK’s vaccine portfolio covers various diseases including hepatitis, diphtheria, tetanus, whooping cough, rotavirus and HPV infections, measles and bacterial meningitis, among others.
GSK plc in the News:-
- 15-Feb-2025 - Penmenvy, GSK’s 5-in-1 meningococcal vaccine, approved by US FDA to help protect against MenABCWY
- 31-Jan-2025 - European Commission authorises ViiV Healthcare’s long-acting injectable Vocabria + Rekambys for HIV treatment in adolescents
- 28-Jan-2025 - Depemokimab accepted for review by the European Medicines Agency for use in asthma with type 2 inflammation and CRSwNP
- 28-Jan-2025 - Depemokimab applications accepted for review in China and Japan for asthma with type 2 inflammation and CRSwNP
- 27-Jan-2025 - GSK and Oxford establish the GSK-Oxford Cancer Immuno-Prevention Programme to advance novel cancer research
- Tactical Analysis:- Various strategic frameworks to gain insights into a company's competitive position and operational environment. These analytical tools assist in identifying competitive advantages, potential risks, and areas for improvement and efficiency, enabling companies to make informed tactical decisions.
- Business Strategy:- Contributes to shaping the company's overall direction, goals, and decision-making processes, ensuring long-term success and alignment with stakeholder expectations.
- Financial Position:- Provide valuable information on the financial performance and investor sentiment surrounding the company. Indicating the level of confidence and expectations in the company's future prospects. These components collectively contribute to understanding the financial health and market perception of the company.
- Company Fundamentals:- These fundamentals offer valuable insights into the company's history, operations, leadership, and geographical presence, aiding in a comprehensive understanding of the organization.
- Competitive Landscape:- An identification of the company's main competitors, providing insights into the competitive landscape it operates in.
- Comprehensive Understanding of the GSK plc's internal and external factors through SWOT analysis, PESTLE analysis, Financial Analysis, and Competitors Benchmarking.
- Strive Strategic Decision Making with various analyses and identifying potential customers and suppliers.
- Mitigate Risk with help of thorough analysis of internal and external factors. Furthermore, develop strategies and contingency plans to address these challenges and minimize their impact on business operations.
- Competitive Benchmarking will help to gain a competitive advantage by understanding industry trends, customer preferences, and best practices.
- Financial Performance Evaluation provides crucial insights into key financial ratios and trends, supporting better financial decision-making and resource allocation.
- Valuable insights from the report enable investors and partners to make informed decisions regarding potential Collaborations, Investments, or Partnerships with the company.
- GSK plc Porter's Five Forces Analysis
- GSK plc VRIO Analysis
- GSK plc BCG Analysis
- GSK plc Segmentation, Targeting and Positioning (STP) Analysis
- GSK plc Ansoff Matrix Analysis
Table of Contents
147 Pages
- COMPANY EXECUTIVE SUMMARY
- Table of Contents
- Tables
- Charts
- GSK plc - Key Company Facts
- GSK plc -
- Company Description
- GSK plc - Top Executives
- GSK plc- Head Office & Locations
- Head Office - Country
- GSK plc - Products and Services
- Products
- Services
- GSK plc - Corporate Strategy
- GSK plc - Business Description
- Vaccines
- Specialty Medicines
- General Medicines
- GSK plc - ESG Spotlight
- Environment
- Social
- Corporate Governance
- GSK plc - SWOT Analysis
- Overview
- Strengths
- Weaknesses
- Opportunities
- Threats
- GSK plc - PESTLE Analysis
- Overview
- Political Factors
- Economic Factors
- Social Factors
- Technological Factors
- Legal Factors
- Environmental Factors
- GSK plc - Chapter1 name
- Heading1
- Heading2
- GSK plc - Chapter1 name
- Heading1
- Heading2
- GSK plc- Chapter1 name
- Heading1
- Heading2
- GSK plc - Financial Deep Dive
- Share Price Trend - Feb-2024 to Feb-2025 (Average Share Closing Price)
- Profit and Loss Statement
- Summary of Profit and Loss Statement
- Balance Sheet
- Summary of Balance Sheet
- Cash Flow Statement
- Summary of Cash Flow Statement
- Key Financial Ratio Analysis
- GSK plc - Ratio Charts
- Activity Ratio Charts
- Growth Ratios Charts
- Leverage Ratio Charts
- Liquidity Ratio Charts
- Profitability Ratio Charts
- Competing Players
- Snapshot of Competing Players
- Roche Holding AG
- Key Company Facts
- Company Description
- Johnson & Johnson
- Key Company Facts
- Company Description
- Novartis AG
- Key Company Facts
- Company Description
- Pfizer Inc.
- Key Company Facts
- Company Description
- Merck & Co., Inc.
- Key Company Facts
- Company Description
- GSK plc - In the News
- 15-Feb-2025 - Penmenvy, GSK's 5-in-1 meningococcal vaccine, approved by US FDA to help protect against MenABCWY
- 31-Jan-2025 - European Commission authorises ViiV Healthcare's long-acting injectable Vocabria + Rekambys for HIV treatment in adolescents
- 28-Jan-2025 - Depemokimab accepted for review by the European Medicines Agency for use in asthma with type 2 inflammation and CRSwNP
- 28-Jan-2025 - Depemokimab applications accepted for review in China and Japan for asthma with type 2 inflammation and CRSwNP
- 27-Jan-2025 - GSK and Oxford establish the GSK-Oxford Cancer Immuno-Prevention Programme to advance novel cancer research
- 27-Jan-2025 - GSK's Shingrix new prefilled syringe presentation accepted for review by European Medicines Agency
- 10-Jan-2025 - GSK's Shingrix new prefilled syringe presentation accepted for review by US FDA
- 23-May-2024 - Statement: Zantac (ranitidine) litigation - Valadez and Williams cases
- 21-May-2024 - GSK announces positive results from phase III severe asthma trials of depemokimab
- 24-Apr-2024 - US FDA accepts for priority review GSK's application for an expanded indication of Jemperli (dostarlimab) plus chemotherapy to include all adult patients with primary advanced or recurrent endometrial cancer
- 17-Apr-2024 - EAGLE-1 phase III data show potential for gepotidacin as a new oral treatment option for uncomplicated urogenital gonorrhoea (GC) amid growing resistance to existing treatments
- 17-Apr-2024 - New long-term data show Shingrix continues to provide high protection against shingles in adults aged 50 and over for more than a decade
- 16-Apr-2024 - GSK's 5-in-1 meningococcal ABCWY vaccine candidate accepted for regulatory review by US FDA
- 16-Mar-2024 - Positive RUBY phase III data show potential for Jemperli (dostarlimab) combinations in more patients with primary advanced or recurrent endometrial cancer
- 07-Mar-2024 - GSK announces positive results from DREAMM-8 phase III trial for Blenrep versus standard of care combination in relapsed/refractory multiple myeloma
- 06-Mar-2024 - ViiV Healthcare announces interim data at CROI indicating superior efficacy of long-acting injectable HIV treatment Cabenuva (cabotegravir + rilpivirine) compared to daily oral therapy in individuals living with HIV who have adherence challenges
- 29-Feb-2024 - GSK announces Dr Jeannie Lee to join the Board as Non-Executive Director
- 28-Feb-2024 - ViiV Healthcare to present data for its next generation of ultra long-acting treatments for HIV
- GSK plc - Key Deals
- 24-Feb-2025 - GSK completes acquisition of IDRx, Inc.
- 13-Jan-2025 - GSK enters agreement to acquire IDRx, Inc.
- 05-Dec-2024 - GSK and Zhifei revise and extend strategic vaccine collaboration in China
- 29-Oct-2024 - GSK enters agreement to acquire CMG1A46 from Chimagen Biosciences to expand immunology pipeline
- 29-Oct-2024 - GSK enters agreement to acquire CMG1A46 from Chimagen Biosciences to expand immunology pipeline
- 21-Oct-2024 - GSK and Cambridge University announce new five-year collaboration in kidney and respiratory disease
- 16-May-2024 - GSK to become a founding partner of Fleming Initiative to fight antimicrobial resistance (AMR)
- 15-Feb-2024 - GSK completes acquisition of Aiolos Bio
- 09-Jan-2024 - GSK enters agreement to acquire Aiolos Bio
- 20-Dec-2023 - GSK enters exclusive license agreement with Hansoh for HS-20093
- 31-Oct-2023 - GSK enters agreement to obtain exclusive license for JNJ-3989 to expand the development of bepirovirsen
- 09-Oct-2023 - GSK and Zhifei announce exclusive strategic vaccine partnership in China
- 28-Jun-2023 - GSK completes acquisition of BELLUS Health
- 18-Apr-2023 - GSK reaches agreement to acquire late-stage biopharmaceutical company BELLUS Health
- 30-Mar-2023 - GSK and SCYNEXIS announce an exclusive agreement to commercialise and further develop Brexafemme (ibrexafungerp), a novel, first-in-class medicine to treat fungal infection
- 13-Dec-2022 - GSK and Wave Life Sciences announce collaboration to drive discovery and development of oligonucleotide therapeutics focusing on novel genetic targets
- Appendix
- Definitions
- SWOT Analysis
- PESTLE Analysis
- Value Chain Analysis
- ESG Spotlight
- Financial Deep Dive
- Financial Ratios -
- Activity Ratios
- Growth Ratios
- Leverage Ratios
- Liquidity Ratios
- Market Ratios
- Profitability Ratios
- Research Methodology
- Disclaimer
- Contact Us
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.